What is the 13F Pro Quality Score for IONS?

13F Pro ranks IONIS PHARMACEUTICALS INC (IONS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IONS's current score at https://13fpro.ai/research/IONS (free sign-up required for the full ranking).

Which hedge funds own the most IONS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IONS include FMR, Capital World Investors, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/IONS as soon as new 13F filings post.

Where does 13F Pro source IONS data?

All IONIS PHARMACEUTICALS INC fundamentals and ownership data come directly from SEC EDGAR. IONIS PHARMACEUTICALS INC files with the SEC under CIK 874015. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IONS in?

IONIS PHARMACEUTICALS INC (IONS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IONS research updated on 13F Pro?

IONS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

IONIS PHARMACEUTICALS INC(IONS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 874015 IONS stock profile & AI dashboard →

13F Pro Quality Score

37.1/100

Rank #2,069 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

87.5/100

Profitability

16.7/100

Balance Sheet

21.0/100

Earnings Quality

30.0/100

Free Cash Flow

7.0/100

Institutional Flow

59.4/100

Revenue Scale

49.2/100

Dilution Risk

4.1/100

IONS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for IONIS PHARMACEUTICALS INC (IONS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IONS at 37.1/100 on a 32-signal composite quality model, placing it at rank #2,069 of 2,879 stocks — the bottom half of the AI-ranked universe. IONS scores in the top quartile across revenue growth (87.5). Areas of concern include free cash flow (7.0) and profitability (16.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), IONIS PHARMACEUTICALS INC reports quarterly revenue of $246.1M, net income of $-92.5M, an operating margin of -47.7%. Top institutional holders of IONS by reported 13-F value include FMR, Capital World Investors, BlackRock,, based on the most recent SEC filings. IONS trades on the Nasdaq exchange and files with the SEC under CIK 874015. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IONS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IONIS PHARMACEUTICALS INC directly from SEC EDGAR. IONIS PHARMACEUTICALS INC's 13F Pro composite quality score has ranged between 8 and 54 since 2021, currently 37.1 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

Revenue

Q1 2026

$246.1M

Net Income

Q1 2026

$-92.5M

Free Cash Flow

Q1 2026

$-814.6M

Operating Margin

Q1 2026

-47.7%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-10.5% YoY

$705.1MFY 2024

FY21 $810.5MFY22 $587.4MFY23 $787.6MFY24 $705.1M

Net Income

-23.9% YoY

$-453.9MFY 2024

FY21 $-28.6MFY22 $-269.7MFY23 $-366.3MFY24 $-453.9M

Operating Income

-34.3% YoY

$-475.1MFY 2024

FY21 $-30.2MFY22 $-410.2MFY23 $-353.7MFY24 $-475.1M

EPS (Diluted)

-18.8% YoY

$-3.04FY 2024

FY21 $-0.20FY22 $-1.90FY23 $-2.56FY24 $-3.04

Total Assets

+0.5% YoY

$3.00BFY 2024

FY21 $2.61BFY22 $2.53BFY23 $2.99BFY24 $3.00B

Total Debt

-4.2% YoY

$1.25BFY 2024

FY21 —FY22 $1.19BFY23 $1.31BFY24 $1.25B

Op. Cash Flow

-62.9% YoY

$-500.9MFY 2024

FY21 $30.8MFY22 $-274.4MFY23 $-307.5MFY24 $-500.9M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$705.1M -10.5%	$787.6M +34.1%	$587.4M -27.5%	$810.5M +11.1%	$729.3M -35.0%	$1.12B
Net Income	$-453.9M -23.9%	$-366.3M -35.8%	$-269.7M -843.2%	$-28.6M +93.6%	$-444.3M -259.7%	$278.1M
Operating Income	$-475.1M -34.3%	$-353.7M +13.8%	$-410.2M -1258.9%	$-30.2M +82.5%	$-172.1M -147.0%	$365.9M
EPS (Diluted)	$-3.04 -18.8%	$-2.56 -34.7%	$-1.90 -850.0%	$-0.20 +93.7%	$-3.18 -267.4%	$1.90
Total Assets	$3.00B +0.5%	$2.99B +18.0%	$2.53B -3.0%	$2.61B +9.3%	$2.39B -26.1%	$3.23B
Total Debt	$1.25B -4.2%	$1.31B +9.6%	$1.19B	—	$839.6M +6.6%	$787.5M
Operating Cash Flow	$-500.9M -62.9%	$-307.5M -12.1%	$-274.4M -990.8%	$30.8M -14.2%	$35.9M -89.6%	$345.6M

AI Insight: IONS Ratio Trends

Ionis remains deeply loss-making across all periods, with ROE hitting -187.6% in Q4 2025 before a single anomalous positive quarter clouds the picture.

• Operating margin has stayed firmly negative every quarter, ranging from -29.3% in Q2 2024 to -111.6% in Q1 2025, with no sustained improvement.

• ROA deteriorated from -9.8% in Q2 2024 to -26.0% in Q4 2025, signaling progressively less efficient asset utilization.

• D/E ratio where reported surged from 2.13 in Q4 2024 to 4.59 in Q4 2025, indicating rapid leverage build-up.

• A single Q4 2025 data row shows 30.9% OpMargin and 88.5% ROIC — an apparent one-off or restatement artifact inconsistent with all other periods.

⚠ ROIC of -95.6% in Q1 2026 is the worst on record; sustained capital destruction at this pace is unsustainable.

⚠ D/E more than doubled in one year to 4.59 — monitor whether debt issuance accelerates or cash burn forces further borrowing.

⚠ The anomalous positive Q4 2025 row warrants clarification; if it reflects a milestone payment or asset sale, recurrence is unlikely.

Get alerted when IONS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for IONIS PHARMACEUTICALS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IONS

FMR LLC
$1.8B24,556,637 sh
Capital World Investors
$1.6B21,186,369 sh
BlackRock, Inc.
$784.1M10,442,476 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$586.4M7,808,902 sh
VANGUARD CAPITAL MANAGEMENT LLC
$534.5M7,118,330 sh
WELLINGTON MANAGEMENT GROUP LLP
$480.0M6,391,816 sh
TWO SIGMA INVESTMENTS, LP
$439.8M5,857,629 sh
GEODE CAPITAL MANAGEMENT, LLC
$305.2M3,984,332 sh
STATE STREET CORP
$300.0M3,995,564 sh
ROYAL BANK OF CANADA
$285.5M3,801,815 sh

Fund	Value	Shares
FMR LLC	$1.8B	24,556,637
Capital World Investors	$1.6B	21,186,369
BlackRock, Inc.	$784.1M	10,442,476
VANGUARD PORTFOLIO MANAGEMENT LLC	$586.4M	7,808,902
VANGUARD CAPITAL MANAGEMENT LLC	$534.5M	7,118,330
WELLINGTON MANAGEMENT GROUP LLP	$480.0M	6,391,816
TWO SIGMA INVESTMENTS, LP	$439.8M	5,857,629
GEODE CAPITAL MANAGEMENT, LLC	$305.2M	3,984,332
STATE STREET CORP	$300.0M	3,995,564
ROYAL BANK OF CANADA	$285.5M	3,801,815

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IONS on your watchlist

Track score changes the day IONIS PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IONS a good stock to buy?

13F Pro's AI-powered analysis of IONIS PHARMACEUTICALS INC (IONS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IONS are available on the IONS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IONS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IONS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IONIS PHARMACEUTICALS INC's investment landscape.